Key result
A pressor response to initial antihypertensive monotherapy was associated with higher cardiovascular mortality compared to a depressor response.
Why the study?
Is a pressor response to initial antihypertensive monotherapy associated with increased cardiovascular mortality in hypertensive patients?
Cohort (n=945)
Is a pressor response to initial antihypertensive monotherapy associated with increased cardiovascular mortality in hypertensive patients?
A paradoxical pressor response to initial antihypertensive monotherapy is independently associated with a 3-fold higher risk of subsequent cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
May warrant closer monitoring of pressor responders; leaves open whether response-guided therapy alters outcomes.
BACKGROUND: A paradoxical pressor systolic response to initial antihypertensive monotherapy has been observed in 8% of hypertensive patients. The long-term consequences of this finding are unknown. METHODS: We included 945 hypertensive patients with baseline systolic blood pressure (SBP) ≥140mm Hg. A 4-week washout period free of antihypertensive drugs was allowed for those already on treatment at entry. Mortality outcomes were ascertained from the National Death Index. Subjects were categorized by SBP response into depressor (≥10mm Hg fall), nonresponder, and pressor (≥10mm Hg rise) categories. RESULTS: There were 268 fatalities. Of these, 100 (37%) were from cardiovascular disease (CVD), of which 70 (70%) were due to coronary artery disease (CAD). A pressor response was associated with higher SBP at 1 year compared with the nonresponder or depressor response (141 vs. 136 vs. 136mm Hg). CVD mortality was greater in pressors than depressors (hazard ratio (HR) = 3.0; 95% confidence interval (CI) = 1.4-6.4; P = 0.004], as was CAD (HR = 3.1; 95% CI = 1.4-6.8; P < 0.01) and all-cause mortality (HR = 1.7; 95% CI = 1.1-2.6; P = 0.02), after adjusting for 1-year SBP and other possible confounders. CONCLUSIONS: We found the incidence of a pressor response to monotherapy at 3 months was significantly, specifically, and independently associated with higher subsequent cardiovascular mortality.
No takes yet. Share an insight, caveat, or question.
Gonzalez et al. (2014) conducted a cohort in Hypertension (n=945). Pressor response to initial antihypertensive monotherapy (≥10 mm Hg rise in SBP) vs. Depressor response (≥10 mm Hg fall in SBP) was evaluated on Cardiovascular disease (CVD) mortality (HR 3.0, 95% CI 1.4-6.4, p=0.004). A pressor response to initial antihypertensive monotherapy was associated with higher cardiovascular mortality compared to a depressor response.
Synapse has enriched 10 related papers. Consider them for comparative context: